Therefore, the prediction of the likelihood of BCR is critical for surveillance strategy of PCa patients and the molecular underpinnings of aggressive and indolent cancers may be essential to improve patient management and prognosis [8]. The gene discussed is BCR; the disease is posterior cortical atrophy.